🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for pMMR

Hypofractionated Radiotherapy Plus Immunotherapy Versus Conventional Radiotherapy in Locally Recurrent Rectal Cancer NCT06928584Phase 21 site📍 Shanghai Fudan University · Tests: Conventional Radiotherapy, Capecitabine, 5-fluorouracil, folinic acid, Oxaliplatin Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma NCT05603910Phase 11 site📍 Miami Aaron Wolfson · Tests: Lenvatinib, Pembrolizumab, Hypofractionated External Beam Radiation Therapy, High-Dose Rate (HDR) Brachytherapy European Collaborative Multicenter Observational Study: Modular Treatment With PMMR and Targeted Compartmental Pelvic Lymphadenectomy Followed by Therapeutic Pelvic and Paraaortic Lymphadenectomy in Node Positive Disease for Locoregional Control in Endometrial Cancer FIGO Stages I-III NCT04504006n/a1 site📍 Essen Dr. Paul Buderath · Tests: Peritoneal Mesometrial Resetion + Targeted Compartmental Lymphadenectomy (PMMR+TCL) Comparing Efficacy and Safety of Enlituo® Versus Erbitux® Plus FOLFOX in Locally Advanced/Metastatic Colorectal Cancer With RAS/BRAF Wild-type and MSS/pMMR Status. NCT07595276Phase 31 site📍 Guangzhou Taizhou Mabtech Pharmaceutical Co.,Ltd · Tests: Enlituo®, Erbitux® Study of GV20-0251 in Participants With Solid Tumor Malignancies NCT07070518Phase 1, Phase 23 sites📍 Beijing📍 Beijing📍 Shanghai GV20 Therapeutics · Tests: GV20-0251 Standard Second-line Therapy With ONgericimab and TOripalimab in pMMR/MSS Colorectal Cancer: a Single-arm Phase II Trial NCT07106034Phase 21 site📍 Shanghai Shanghai Pudong Hospital · Tests: Ongericimab + Toripalimab + Bevacizumab + FOLFOX, Ongericimab + Toripalimab + Bevacizumab + FOLFIRI Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer NCT07528209Phase 31 site📍 Guangzhou Sun Yat-sen University · Tests: Pucotenlimab combine with CAPOX, CAPOX Treating Locally Advanced Rectal Cancer With TAS-102 Chemotherapy Plus Neoadjuvant Radiotherapy NCT05965531Phase 21 site📍 Guangzhou Sun Yat-sen University · Tests: Trifluridine/Tipiracil, intensity-modulated radiotherapy Short-course Radiotherapy Followed by Sequential Chemotherapy With or Without PD-1 Monoclonal Antibody and Bevacizumab as Total Neoadjuvant Therapy in pMMR/MSS Locally Advanced Rectal Cancer （SPARK） NCT07005570Phase 21 site📍 Guangzhou Dechang Diao · Tests: Short-course radiotherapy followed by sequential chemotherapy combined with PD-1 monoclonal antibody and bevacizumab, S… Modified Long-Course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor for MSS/pMMR High-risk Mid/Low LARC (MODIFI-RC-I) NCT06923345Phase 21 site📍 Guangzhou Sixth Affiliated Hospital, Sun Yat-sen University · Tests: Reduced CTV, Conventional CTV Short-Course Radiotherapy Followed by CAPOX With or Without Iparomlimab and Tuvonralimab in pMMR/MSS Locally Advanced Rectal Cancer NCT07686640Phase 31 site📍 Jinan Shandong Cancer Hospital and Institute · Tests: Short-Course Radiotherapy, Consolidation treatment (With ICIs), Consolidation treatment (Without ICIs) Tafolecimab Combined With Chemoimmunotherapy as Neoadjuvant Treatment for pMMR/MSS Locally Advanced Colon Cancer NCT07840677Phase 21 site📍 Chongqing Daping Hospital and the Research Institute of Surgery of th… · Tests: Tafolecimab, Sintilimab Sequential Immunochemotherapy Treatment with Pembrolizumab Plus Dendritic Cell (DC) Vaccine Followed by Trifluridine/Tipiracil Plus Bevacizumab in Refractory Mismatch-repair-proficient (pMMR) or Microsatellite-stable (MSS) Metastatic Colorectal Cancer NCT06522919Phase 22 sites📍 Meldola📍 Tricase Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IR… · Tests: Autologous Dendritic Cell (DC) Vaccine Immunotheray Combined With Simvastatin and Target Therapy and Chemotharepy for Advanced Colorectal Cancer NCT07718490Phase 22 sites📍 Nanjing📍 Nanjing The First Affiliated Hospital with Nanjing Medical Universi… · Tests: Adebrelimab A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies NCT05669430Phase 1, Phase 213 sites📍 Los Angeles📍 Denver📍 New Haven GV20 Therapeutics · Tests: GV20-0251, GV20-0251, GV20-0251 and Pembrolizumab [KEYTRUDA®], GV20-0251 and Pembrolizumab [KEYTRUDA®] Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) NCT05579366Phase 1, Phase 266 sites📍 Phoenix📍 Tucson📍 Los Angeles Genmab · Tests: Rina-S, Carboplatin, Bevacizumab, Pembrolizumab, Erythromycin Radiotherapy + Systemic Therapy as Conversion Therapy for pMMR/MSS T4M0 Colon Cancer（Neo-Color） NCT06949111Phase 21 site📍 Shijiazhuang Hebei Medical University Fourth Hospital · Tests: radiotherapy, CAPOX, Capecitabine, Iparomlimab and Tuvonralimab Injection The Efficacy and Safety of Short-course Radiation Combined With Adebrelimab and CAPEOX Neo-adjuvant Therapy for Organ-retention in Patients With MSS/pMMR Ultra Low Rectal Adenocarcinoma NCT06266832Phase 21 site📍 Hangzhou Sir Run Run Shaw Hospital · Tests: Adebrelimab, Oxaliplatin, Capecitabine, Short-course Radiation, Biopsy Perioperative Chemotherapy Combined With Serplulimab or Placebo for pMMR Locally Advanced Gastric Adenocarcinoma (FOCUS-05) NCT05872685Phase 25 sites📍 Hangzhou📍 Hangzhou📍 Lishui Yu jiren · Tests: S1, Oxaliplatin, Serplulimab, Placebo Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease NCT07750158Phase 313 sites📍 Council Bluffs📍 Grand Island📍 Grand Island Exelixis · Tests: Zanzalintinib, Pembrolizumab (+) Berahyaluronidase alfa, Placebo Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer NCT07198074Phase 3304 sites📍 Birmingham📍 Anchorage📍 Phoenix National Cancer Institute (NCI) · Tests: Bevacizumab, Biospecimen Collection, Carboplatin, Computed Tomography, Magnetic Resonance Imaging HDAC Inhibitor Combination With Chemoimmunotherapy in the Neoadjuvant Treatment of pMMR Locally Advanced Colon Cancer NCT06709885Phase 21 site📍 Chongqing Daping Hospital and the Research Institute of Surgery of th… · Tests: Chidamide + Tislelizumab + chemotherapy (CapeOX ), CapeOX A Multicenter, Randomized Controlled Phase II Study of Short-Course Radiotherapy Followed by Sequential PD-1 Inhibitor and FOLFOX Chemotherapy Versus Long-Course Chemoradiotherapy for High-Risk Locally Advanced pMMR/MSS Lower Rectal Adenocarcinoma (STAR Trial) NCT07669220Phase 21 site📍 Guangzhou Sixth Affiliated Hospital, Sun Yat-sen University · Tests: Short-course Radiotherapy, SCRT, Toripalimab A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients NCT06497985Phase 31 site📍 Guangzhou Chipscreen Biosciences, Ltd. · Tests: Tucidinostat, Sintilimab, Bevacizumab, Fruquintinib mFOLFOX6 + Bevacizumab + PD-1 Monoclonal Antibody Vs. mFOLFOX6 in Locally Advanced pMMR/MSS CRC NCT06791512Phase 31 site📍 Guangzhou Jun Huang · Tests: mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody, mFOLFOX6 Patient-reported Outcomes (PRO) and Treatment Outcomes of Chinese Patients With MSS-type Advanced Colorectal Cancer Who Received the Zidovudine Combination Regimen in the Real World NCT07105631n/a1 site📍 Chengdu West China Hospital Study on the Efficacy and Safety of Neoadjuvant Radiotherapy Combined With Tislelizumab, Liposomal Irinotecan, and Capecitabine in the Treatment of pMMR Locally Advanced Rectal Adenocarcinoma With Low Rectal Involvement NCT07104604Phase 22 sites📍 Shantou📍 Shantou Affiliated Cancer Hospital of Shantou University Medical Co… · Tests: Liposomal Irinotecan+Tislelizumab+Capecitabine+Rradiotherapy NIS to Examine the Effectiveness and Safety of Durvalumab and Olaparib in Patients With Endometrial Cancer (DUOLife) NCT06890273n/a49 sites📍 Amberg📍 Bad Nauheim📍 Bautzen AstraZeneca Neoadjuvant Chemoradiotherapy Plus Tislelizumab With or Without Probio-M9 in pMMR/MSS Locally Advanced Rectal Cancer NCT07458529Phase 21 site📍 Beijing Seventh Medical Center of PLA General Hospital · Tests: CRT+PD-1 inhibitor+Probio-M9, CRT+PD-1 inhibitor+placebo SCRT Combined With Chemotherapy and Iparomlimab and Tuvonralimab in MSS or pMMR Patients With Locally Advanced Rectal Cancer NCT06864013Phase 21 site📍 Hangzhou First Affiliated Hospital of Zhejiang University · Tests: Experimental, Control
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy